Congress Proposes Expanding Medicare Coverage for New Lung Cancer Screening Tests
This bill is currently sitting in the House committees on Energy and Commerce and Ways and Means. It is considered stalled because no action has been taken on it since February 2025. The bill will not move forward unless these committees decide to review it.
No action since February 2025
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 6693 (118th), which died when its Congress ended.
H.R. 6693 (118th) →Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
This bill would let Medicare cover new types of lung cancer screening tests beyond what's currently allowed under existing rules. Right now, Medicare mainly covers low-dose CT scans for lung cancer screening. If passed, the Secretary of Health and Human Services could approve coverage of newer FDA-cleared tests — like blood-based biomarker tests — giving seniors more options for catching lung cancer early when it's most treatable. This could particularly help the millions of Medicare beneficiaries who are at higher risk due to smoking history or age.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Lung Cancer Screening and Prevention Act of 2025
Analysis generated by AI. Always verify with official sources.